484 related articles for article (PubMed ID: 17727803)
1. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
3. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.
Blackstone EA; Fuhr JP
Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836
[TBL] [Abstract][Full Text] [Related]
6. Assessing the bioequivalence of biosimilars The Retacrit case.
Schellekens H
Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars--global issues, national solutions.
Knezevic I; Griffiths E
Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
[TBL] [Abstract][Full Text] [Related]
9. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
[TBL] [Abstract][Full Text] [Related]
10. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
11. Immunogenicity of biopharmaceuticals.
Kessler M; Goldsmith D; Schellekens H
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v9-12. PubMed ID: 16959792
[TBL] [Abstract][Full Text] [Related]
12. Concept of biosimilar products in Jordan.
Haddadin RD
Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
[TBL] [Abstract][Full Text] [Related]
13. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: how similar or dissimilar are they?
Roger SD
Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
[TBL] [Abstract][Full Text] [Related]
15. Follow-on biologics: challenges of the "next generation".
Schellekens H
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: recent developments.
Covic A; Kuhlmann MK
Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: pharmacovigilance and risk management.
Zuñiga L; Calvo B
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
[TBL] [Abstract][Full Text] [Related]
18. Are biosimilars really generics?
Misra A
Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
Malhotra H
Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
[TBL] [Abstract][Full Text] [Related]
20. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
